Bioactive Mediator Profile of Mepolizumab‐Treated Eosinophilic Granulomatosis With Polyangiitis
The data that support the findings of this study are available from the corresponding author upon reasonable request. Table S1. Data S1. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Authors
- Kiyoshi Sekiya
- Yukinori Okada (ORCID: https://orcid.org/0000-0002-0311-8472)
- Yosuke Kamide (ORCID: https://orcid.org/0000-0002-7185-2273)
- Shigeharu Ueki (ORCID: https://orcid.org/0000-0002-3537-7735)
- Kyuto Sonehara (ORCID: https://orcid.org/0000-0002-4536-1761)
- Yuto Nakamura (ORCID: https://orcid.org/0009-0002-5388-8245)
- Masami Taniguchi
Institutions
- Akita University (JP)
- National Sagamihara Hospital (JP)
- Shonan Kamakura General Hospital (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Allergy
- Published
- 2024-11-11
- DOI
- https://doi.org/10.1111/all.16395
- Citations
- 2
- Primary Topic
- Eosinophilic Disorders and Syndromes
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- GlaxoSmithKline
- Japan Agency for Medical Research and Development
- Ministry of Health, Labour and Welfare
- Japan Society for the Promotion of Science